Mercks phase 3 KEYNOTE-412 trial of Keytruda to treat patients with unresected locally advanced HNSCC fails to meet primary endpoint

Merck, known as MSD outside the United States and Canada, announced that the phase 3 KEYNOTE-412 trial evaluating Keytruda (pembrolizumab), Merck